WO2019066752A2 - Vagus nerve stimulator with antimicrobial characteristic - Google Patents

Vagus nerve stimulator with antimicrobial characteristic Download PDF

Info

Publication number
WO2019066752A2
WO2019066752A2 PCT/TR2018/050246 TR2018050246W WO2019066752A2 WO 2019066752 A2 WO2019066752 A2 WO 2019066752A2 TR 2018050246 W TR2018050246 W TR 2018050246W WO 2019066752 A2 WO2019066752 A2 WO 2019066752A2
Authority
WO
WIPO (PCT)
Prior art keywords
vagus nerve
antimicrobial
polymeric layer
nerve stimulator
stimulator
Prior art date
Application number
PCT/TR2018/050246
Other languages
French (fr)
Other versions
WO2019066752A3 (en
Inventor
Hayati DENIZ
Original Assignee
Deniz Hayati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deniz Hayati filed Critical Deniz Hayati
Publication of WO2019066752A2 publication Critical patent/WO2019066752A2/en
Publication of WO2019066752A3 publication Critical patent/WO2019066752A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0551—Spinal or peripheral nerve electrodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/36053—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for vagal stimulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36064—Epilepsy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36078—Inducing or controlling sleep or relaxation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36082—Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease

Definitions

  • the present invention relates to a vagus nerve stimulator used for supporting the treatment of some neurologic diseases and provided with antimicrobial characteristic in a manner preventing infection formation in the body after surgical operation.
  • the present invention relates to providing antimicrobial characteristic to all accessories and components of vagus nerve stimulators used for supporting the treatment of diseases like epilepsy, depression, panic attack, Alzheimer, sleep apnea and for supporting obesity treatment.
  • Vagus nerve stimulators are used for supporting the treatment of diseases like epilepsy, depression, panic attack, Alzheimer, sleep apnea, etc.
  • the use of vagus nerve stimulators particularly in epilepsy diseases decreases or ends the frequency and intensity of epileptic seizures. Therefore, their uses increase day by day.
  • Vagus nerve stimulators are placed to the body of the patient by means of surgical operations and they stay in a permanent manner in the body of the patient.
  • vagus nerve stimulators in the surgical operations applied in placing of the vagus nerve stimulators to the body, hygienic operation conditions shall be provided and moreover, the stimulator shall also be sterilized.
  • infection formation risk occurs, which results from vagus nerve stimulator inside the body.
  • epilepsy disease the patient shall use big number of drugs and these drugs have many side effects. One of these side effects is the bone marrow suppression and this leads to weakening of the immunity system and makes the body prone to infections.
  • the patients where epilepsy is observed are generally child patients and this increases the risk of infection of the patients.
  • the electrodes of vagus nerve stimulators are adapted into the body in a manner encircling the vagus nerve from 3 separate locations.
  • the present invention relates to a vagus nerve stimulator provided with antimicrobial characteristic by means of applying a polymeric layer comprising metal ions, for eliminating the above mentioned disadvantages and for bringing new advantages to the related technical field.
  • the main object of the present invention is to provide a vagus nerve stimulator where infection formation is eliminated in all components placed into the body.
  • Another object of the present invention is to provide a vagus nerve stimulator which eliminates the secondary surgical operations realized depending on infection.
  • the present invention is a vagus nerve stimulator positioned in the region inside the body and which stays in the region it is placed in a permanent manner and having stimulator components which incorporate with the vagus nerve and the peripheral tissues.
  • said vagus nerve stimulator is characterized by comprising an antimicrobial polymeric layer applied by means of covalent bonds, such that no gap remains, through a holding surface to the whole outer casing of the stimulator components which remain inside the body in a manner preventing formation of bio-film by the bacteria in order to prevent infection risk in the regions inside the body.
  • said antimicrobial polymeric layer comprises said antimicrobial nano-particles which provide cell fragmentation and which inactivate bacteria.
  • said antimicrobial nano-particles comprise antimicrobial ions which spread to the body inner region through a diffusion surface of the polymeric layer.
  • the organic compound provided at the polymeric layer is selected as one of halogenated diphenyl ethers, phenol compounds, halophenoics and bisphenolic compounds, resorcinol and derivatives, benzoic esters, quaternary ammonium compounds.
  • the anorganic compound provided at the polymeric layer is selected as one of zeolites, NaAI silicate.
  • Figure 1 is the schematic view of the vagus nerve stimulator component with antimicrobial characteristic.
  • Figure 2 is the schematic view of the bacteria killing mechanism of the antimicrobial polymeric layer.
  • vagus nerve stimulator with antimicrobial characteristic is explained with references to examples without forming any restrictive effect only in order to make the subject more understandable.
  • Vagus nerve stimulator is an active implant placed to the inner region (30) of the body and comprises pluralities of components.
  • FIG 1 a detailed schematic view of a stimulator component (10) is given.
  • the antimicrobial polymeric layer (20) is provided on the stimulator component (10).
  • Said antimicrobial polymeric layer (20) is bonded by means of covalent bonds onto the outer casing (1 1 ) of the stimulator component (10).
  • the antimicrobial polymeric layer (20) comprises a holding surface (21 ) connected to said outer casing (1 1 ) and a diffusion surface (22).
  • the antimicrobial polymeric layer (20) is provided in the form of a thin film on the stimulator component (10).
  • This film layer is provided by means of applying the synthesized polymer onto the outer casing (1 1 ) after the polymer is dissolved in a solvent.
  • the polymer layer (10) shall be distributed on the outer casing (1 1 ) in a non-gapped and substantially homogeneous manner. In cases where there are gaps, the bacteria (40) colonies may augment in these gaps and may form bio-film.
  • the polymer layer (20) shall show selective characteristic. In other words, while the polymer layer (20) eliminates bacteria (40) in a rapid and effective manner, it shall give minimum damage to the blood and tissue cells, and even, it shall give no damage to the blood and tissue cells.
  • the components, forming the antimicrobial polymeric layer (20), comprise metals and organic and anorganic compounds which adhere onto the bacteria (40) and which prevent bio-film formation.
  • organic compounds halogenated diphenyl ethers, phenol compounds, halophenoics and bisphenolic compounds, resorcinol and derivatives, benzoic esters, quaternary ammonium compounds can be used.
  • anorganic compounds zeolites and NaAI silicate can be used.
  • metal silver, zinc or copper is preferred.
  • the elimination mechanism of the bacteria (40) by the antimicrobial polymeric layers (20) is given in Figure 2 and the operation mechanism operates as follows; while the antimicrobial polymeric layer (20) is + charged, the surfaces of the bacteria (40) forming infection are - charged and this elimination function occurs as a result of interaction of these + and - charges.
  • the bacteria shall contact the polymeric layer (20).
  • the antimicrobial nano particles (23) interact with the bacteria (40).
  • the membranes of the bacteria (40) are fragmented as a result of the effect of the phospholipids existing on the surface of the bacteria (40).
  • Nano-particles (23) bind to the cell walls of the bacteria (40) and they form gaps at the cell membrane and they deteriorate the balance of the proton channels and they lead to cell fragmentation. Except contact to the polymeric layer (20), the antimicrobial ions (231 ) spreading to the body inner region (30) from the diffusion surface (22) of the nano-particles (23) contribute to fragmentation of the bacteria (40) by means of a similar mechanism.
  • Microorganisms can gain resistance against various media. This leads to production of microorganism. Particularly the microorganisms, which are naturally more resistant when compared with other microorganisms, can gain resistance more easily against any antimicrobial disinfectant as a result of long contact durations. When the microorganisms stay for long duration in the disinfectant solution, they may gain resistance as in the antibiotics and they may stay vital and even they may continue to reproduce. If the active substance existing in the disinfectant or in the antiseptic preparation is not at a sufficient amount and if the active substance existing in the disinfectant or in the antiseptic preparation is not at a concentration in a manner preventing living of the microorganism, the resistance of the microorganism increases. Therefore, only disinfectant is not sufficient.
  • vagus nerve stimulator The greatest advantage presented by the subject matter vagus nerve stimulator is that the antimicrobial polymeric layer (20) can clean itself automatically and it prevents reproduction and spreading of the bacteria (40).
  • the antimicrobial polymeric layer (20) is resistant against the disinfectant and detergents. Thanks to its brilliant and smooth surface, holding of foreign substances like dust, etc. is prevented.
  • Vagus nerve stimulators are used as a treatment device which is additional to the treatment of various neurologic diseases, essentially treatment of epilepsy.
  • all components of stimulators are coated by antimicrobial polymeric later (20)
  • the infections in the body inner region (30) which result from stimulators are eliminated.
  • infection formation risk is eliminated and the secondary surgeries which may occur due to infection are eliminated, and the infection treatments are eliminated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Electrotherapy Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is a vagus nerve stimulator positioned in the region inside the body (30) and which stays in the region it is placed in a permanent manner and having stimulator components (10) which incorporate with the vagus nerve and the peripheral tissues, said vagus nerve stimulator is characterized by comprising an antimicrobial polymeric layer (20) applied by means of covalent bonds, such that no gap remains, through a holding surface (21) to the whole outer casing (11) of the stimulator components (10) which remain inside the body in a manner preventing formation of bio-film by the bacteria (40) in order to prevent infection risk in the regions inside the body (30).

Description

VAGUS NERVE STIMULATOR WITH ANTIMICROBIAL CHARACTERISTIC TECHNICAL FIELD
The present invention relates to a vagus nerve stimulator used for supporting the treatment of some neurologic diseases and provided with antimicrobial characteristic in a manner preventing infection formation in the body after surgical operation.
The present invention relates to providing antimicrobial characteristic to all accessories and components of vagus nerve stimulators used for supporting the treatment of diseases like epilepsy, depression, panic attack, Alzheimer, sleep apnea and for supporting obesity treatment.
PRIOR ART
Neurology is the science branch where brain, brain stem, vertebra and peripheral nerve system and muscle diseases are worked on. Neurologic diseases may show effect on very different and various locations of the nerve system and they may occur with various complaints in the patients. Treatment in neurologic diseases is applied depending on the disease and the patient. Vagus nerve stimulators are used for supporting the treatment of diseases like epilepsy, depression, panic attack, Alzheimer, sleep apnea, etc. The use of vagus nerve stimulators particularly in epilepsy diseases decreases or ends the frequency and intensity of epileptic seizures. Therefore, their uses increase day by day. Vagus nerve stimulators are placed to the body of the patient by means of surgical operations and they stay in a permanent manner in the body of the patient. Therefore, in the surgical operations applied in placing of the vagus nerve stimulators to the body, hygienic operation conditions shall be provided and moreover, the stimulator shall also be sterilized. In the opposite case, infection formation risk occurs, which results from vagus nerve stimulator inside the body. In epilepsy disease, the patient shall use big number of drugs and these drugs have many side effects. One of these side effects is the bone marrow suppression and this leads to weakening of the immunity system and makes the body prone to infections. Moreover, the patients where epilepsy is observed are generally child patients and this increases the risk of infection of the patients. The electrodes of vagus nerve stimulators are adapted into the body in a manner encircling the vagus nerve from 3 separate locations. After the surgical operation is completed, granulation process begins and adhesions occur by means of fibrosis. This means incorporation of the electrode to the body. Thus, in case of any infection which occurs after this step, removal of the electrode becomes difficult and permanent damage may occur in the nerve even during the removal of the electrode. In the devices placed to the body, it is not important which device component is infected, and the whole device shall be removed and afterwards, the patient shall be subjected to infection treatment and afterwards, a secondary placement operation is needed. Each surgery realized affects the patients and the patients' relatives in an unfavorable manner in terms of financial and physiologic terms and the recovery durations after surgeries also increase.
As a result, because of all of the abovementioned problems, an improvement is required in the related technical field.
BRIEF DESCRIPTION OF THE INVENTION
The present invention relates to a vagus nerve stimulator provided with antimicrobial characteristic by means of applying a polymeric layer comprising metal ions, for eliminating the above mentioned disadvantages and for bringing new advantages to the related technical field.
The main object of the present invention is to provide a vagus nerve stimulator where infection formation is eliminated in all components placed into the body.
Another object of the present invention is to provide a vagus nerve stimulator which eliminates the secondary surgical operations realized depending on infection.
In order to realize all of the abovementioned objects and the objects which are to be deducted from the detailed description below, the present invention is a vagus nerve stimulator positioned in the region inside the body and which stays in the region it is placed in a permanent manner and having stimulator components which incorporate with the vagus nerve and the peripheral tissues. Accordingly, said vagus nerve stimulator is characterized by comprising an antimicrobial polymeric layer applied by means of covalent bonds, such that no gap remains, through a holding surface to the whole outer casing of the stimulator components which remain inside the body in a manner preventing formation of bio-film by the bacteria in order to prevent infection risk in the regions inside the body. In a preferred embodiment of the present invention, said antimicrobial polymeric layer comprises said antimicrobial nano-particles which provide cell fragmentation and which inactivate bacteria. In another preferred embodiment of the present invention, said antimicrobial nano-particles comprise antimicrobial ions which spread to the body inner region through a diffusion surface of the polymeric layer.
In another preferred embodiment of the present invention, the organic compound provided at the polymeric layer is selected as one of halogenated diphenyl ethers, phenol compounds, halophenoics and bisphenolic compounds, resorcinol and derivatives, benzoic esters, quaternary ammonium compounds.
In another preferred embodiment of the present invention, the anorganic compound provided at the polymeric layer is selected as one of zeolites, NaAI silicate.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 is the schematic view of the vagus nerve stimulator component with antimicrobial characteristic.
Figure 2 is the schematic view of the bacteria killing mechanism of the antimicrobial polymeric layer. REFERENCE NUMBERS
10 Stimulator Component
1 1 Outer Casing
20 Antimicrobial Polymeric Layer
21 Holding Surface
22 Diffusion Surface
23 Antimicrobial Nano Particle
231 Antimicrobial Ion
30 Body Inner Region
40 Bacteria DETAILED DESCRIPTION OF THE INVENTION
In this detailed description, the subject matter vagus nerve stimulator with antimicrobial characteristic is explained with references to examples without forming any restrictive effect only in order to make the subject more understandable.
Vagus nerve stimulator is an active implant placed to the inner region (30) of the body and comprises pluralities of components. In Figure 1 , a detailed schematic view of a stimulator component (10) is given. Accordingly, the antimicrobial polymeric layer (20) is provided on the stimulator component (10). Said antimicrobial polymeric layer (20) is bonded by means of covalent bonds onto the outer casing (1 1 ) of the stimulator component (10). The antimicrobial polymeric layer (20) comprises a holding surface (21 ) connected to said outer casing (1 1 ) and a diffusion surface (22). There are antimicrobial nano-particles (23) inside the polymeric layer (20). Moreover, there are antimicrobial ions (231 ) on the diffusion surface (22) and on the inner region of the body in a distributed manner.
The antimicrobial polymeric layer (20) is provided in the form of a thin film on the stimulator component (10). This film layer is provided by means of applying the synthesized polymer onto the outer casing (1 1 ) after the polymer is dissolved in a solvent. The polymer layer (10) shall be distributed on the outer casing (1 1 ) in a non-gapped and substantially homogeneous manner. In cases where there are gaps, the bacteria (40) colonies may augment in these gaps and may form bio-film. The polymer layer (20) shall show selective characteristic. In other words, while the polymer layer (20) eliminates bacteria (40) in a rapid and effective manner, it shall give minimum damage to the blood and tissue cells, and even, it shall give no damage to the blood and tissue cells.
The components, forming the antimicrobial polymeric layer (20), comprise metals and organic and anorganic compounds which adhere onto the bacteria (40) and which prevent bio-film formation. Within this scope, as organic compounds, halogenated diphenyl ethers, phenol compounds, halophenoics and bisphenolic compounds, resorcinol and derivatives, benzoic esters, quaternary ammonium compounds can be used. As anorganic compounds, zeolites and NaAI silicate can be used. As metal; silver, zinc or copper is preferred.
The elimination mechanism of the bacteria (40) by the antimicrobial polymeric layers (20) is given in Figure 2 and the operation mechanism operates as follows; while the antimicrobial polymeric layer (20) is + charged, the surfaces of the bacteria (40) forming infection are - charged and this elimination function occurs as a result of interaction of these + and - charges. For providing the interaction, the bacteria shall contact the polymeric layer (20). By means of this contact, the antimicrobial nano particles (23) interact with the bacteria (40). By means of this interaction, the membranes of the bacteria (40) are fragmented as a result of the effect of the phospholipids existing on the surface of the bacteria (40). Nano-particles (23) bind to the cell walls of the bacteria (40) and they form gaps at the cell membrane and they deteriorate the balance of the proton channels and they lead to cell fragmentation. Except contact to the polymeric layer (20), the antimicrobial ions (231 ) spreading to the body inner region (30) from the diffusion surface (22) of the nano-particles (23) contribute to fragmentation of the bacteria (40) by means of a similar mechanism.
Microorganisms can gain resistance against various media. This leads to production of microorganism. Particularly the microorganisms, which are naturally more resistant when compared with other microorganisms, can gain resistance more easily against any antimicrobial disinfectant as a result of long contact durations. When the microorganisms stay for long duration in the disinfectant solution, they may gain resistance as in the antibiotics and they may stay vital and even they may continue to reproduce. If the active substance existing in the disinfectant or in the antiseptic preparation is not at a sufficient amount and if the active substance existing in the disinfectant or in the antiseptic preparation is not at a concentration in a manner preventing living of the microorganism, the resistance of the microorganism increases. Therefore, only disinfectant is not sufficient. The greatest advantage presented by the subject matter vagus nerve stimulator is that the antimicrobial polymeric layer (20) can clean itself automatically and it prevents reproduction and spreading of the bacteria (40). The antimicrobial polymeric layer (20) is resistant against the disinfectant and detergents. Thanks to its brilliant and smooth surface, holding of foreign substances like dust, etc. is prevented.
Vagus nerve stimulators are used as a treatment device which is additional to the treatment of various neurologic diseases, essentially treatment of epilepsy. By means of said invention, since all components of stimulators are coated by antimicrobial polymeric later (20), the infections in the body inner region (30) which result from stimulators are eliminated. Thus, particularly in the process after surgical operation, infection formation risk is eliminated and the secondary surgeries which may occur due to infection are eliminated, and the infection treatments are eliminated. The protection scope of the present invention is set forth in the annexed Claims and cannot be restricted to the illustrative disclosures given above, under the detailed description. It is because a person skilled in the relevant art can obviously produce similar embodiments under the light of the foregoing disclosures, without departing from the main principles of the present invention.

Claims

1. A vagus nerve stimulator positioned in the region inside the body (30) and which stays in the region it is placed in a permanent manner and having stimulator components (10) which incorporate with the vagus nerve and the peripheral tissues, said vagus nerve stimulator is characterized by comprising an antimicrobial polymeric layer (20) applied by means of covalent bonds, such that no gap remains, through a holding surface (21 ) to the whole outer casing (1 1 ) of the stimulator components (10) which remain inside the body in a manner preventing formation of bio-film by the bacteria (40) in order to prevent infection risk in the regions inside the body (30).
2. A vagus nerve stimulator according to claim 1 , wherein said antimicrobial polymeric layer (20) comprises said antimicrobial nano-particles (23) which provide cell fragmentation and which inactivate bacteria (40).
3. A vagus nerve stimulator according to claim 1 or 2, wherein said antimicrobial nano- particles (23) comprise antimicrobial ions (231 ) which spread to the body inner region (30) through a diffusion surface (22) of the polymeric layer (20).
4. A vagus nerve stimulator according to claim 1 , wherein the organic compound provided at the polymeric layer (20) is selected as one of halogenated diphenyl ethers, phenol compounds, halophenoics and bisphenolic compounds, resorcinol and derivatives, benzoic esters, quaternary ammonium compounds.
5. A vagus nerve stimulator according to claim 1 , wherein the anorganic compound provided at the polymeric layer (20) is selected as one of zeolites, NaAI silicate.
PCT/TR2018/050246 2017-06-12 2018-05-17 Vagus nerve stimulator with antimicrobial characteristic WO2019066752A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/08610 2017-06-12
TR2017/08610A TR201708610A2 (en) 2017-06-12 2017-06-12 VAGUS NERVE STIMULATOR WITH ANTIMICROBIAL PROPERTIES

Publications (2)

Publication Number Publication Date
WO2019066752A2 true WO2019066752A2 (en) 2019-04-04
WO2019066752A3 WO2019066752A3 (en) 2019-05-16

Family

ID=65902664

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2018/050246 WO2019066752A2 (en) 2017-06-12 2018-05-17 Vagus nerve stimulator with antimicrobial characteristic

Country Status (2)

Country Link
TR (1) TR201708610A2 (en)
WO (1) WO2019066752A2 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8309117B2 (en) * 2002-12-19 2012-11-13 Novartis, Ag Method for making medical devices having antimicrobial coatings thereon
US20040186528A1 (en) * 2003-03-20 2004-09-23 Medtronic, Inc. Subcutaneous implantable medical devices with anti-microbial agents for chronic release
US8425926B2 (en) * 2003-07-16 2013-04-23 Yongxing Qiu Antimicrobial medical devices
US20110021899A1 (en) * 2009-07-23 2011-01-27 Surmodics, Inc. Conductive polymer coatings

Also Published As

Publication number Publication date
WO2019066752A3 (en) 2019-05-16
TR201708610A2 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
US8133215B2 (en) Independently-manufactured drug delivery module and corresponding receptacle in an implantable medical device
JP6509892B2 (en) Device for treating body surface of living body
US8160714B2 (en) Complementary drug delivery sheath for an implantable medical device
Bas et al. Conservation of hearing and protection of hair cells in cochlear implant patients' with residual hearing
Vivero et al. Dexamethasone base conserves hearing from electrode trauma‐induced hearing loss
Zhang et al. Biological properties of an anti‐bacterial membrane for guided bone regeneration: an experimental study in rats
DE102009014771A1 (en) Percutaneous hearing aid implant for permanent anchoring in skull bone of patient, has counter bearing provided with outer surface, where antibacterial coating is applied on inner part of bearing and/or bone fastener and/or surface of screw
Alvarez-Lorenzo et al. Smart drug release from medical devices
US20210393680A1 (en) Use of an antimicrobial composition
US20170216022A1 (en) Drug-Eluting Stapes Prosthesis
WO2019066752A2 (en) Vagus nerve stimulator with antimicrobial characteristic
Leso et al. Opportunities and challenging issues of nanomaterials in otological fields: An occupational health perspective
KR20100017345A (en) Biocidic medical devices, implants and wound dressings
Ghazi et al. Evaluation of adding nanosized natural zeolite to photodynamic therapy against P. gingivalis biofilm on titanium disks
EP2512589B1 (en) Device for administering drugs and for influencing the effects of drugs
WO2006126312A1 (en) Medical instrument using photocatalyst
Lenarz et al. Preserving residual hearing in cochlear implant patients
EP4079340A1 (en) A dressing comprising an antimicrobial coating
DE20321445U1 (en) Otorhinological dispenser
WO2023034771A1 (en) Devices and methods for treating infected tissue
Costerton Chalmers j. lyons memorial lecture. Presented on Thursday, September 11, 1: 00 pm–2: 30 pm: The role of biofilms in device-related and other chronic bacterial infections
Yu et al. General introduction and aim of the thesis
RU2324499C2 (en) Method of prevention of purulent process in post-operational osseous defect
WO2022132628A1 (en) Kits, systems, and methods for reducing surgical site infections
KR20130020230A (en) Pharmaceutical composition comprising necrox for preventing or treating hearing loss

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18861211

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 16.03.2020)

122 Ep: pct application non-entry in european phase

Ref document number: 18861211

Country of ref document: EP

Kind code of ref document: A2